Retatrutide, Lilly's Triple-Hormone Agonist, Posts 28% Weight Loss in Its Pivotal Obesity Trial
The largest and longest trial yet of a drug that hits three gut-hormone receptors at once points to a new efficiency ceiling for obesity medicines, though these are topline results, not yet peer-reviewed.
Eli Lilly reported topline results on May 21, 2026 from TRIUMPH-1, the largest and longest Phase 3 obesity trial to read out so far for retatrutide, its investigational “triple-G” agonist. (Retatrutide’s first Phase 3 readout came earlier, in December 2025, from TRIUMPH-4, a study in obesity with knee osteoarthritis.) The compound activates three receptors at once: GLP-1, GIP, and glucagon, one more than tirzepatide (marketed as Zepbound), which engages GLP-1 and GIP. That extra target, glucagon, is thought to raise energy expenditure, and the trial’s numbers suggest the mechanism translates into unusually deep weight loss.
TRIUMPH-1 (NCT05929066) randomized 2,339 adults with obesity, or overweight plus at least one weight-related complication, none of whom had diabetes. Participants received once-weekly retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks. At the highest dose, average weight loss reached 28.3% (about 70.3 lbs), versus 2.2% (5.5 lbs) on placebo. The 9 mg and 4 mg arms lost 25.9% and 19.0%. Nearly half of the 12 mg group (45.3%) shed at least 30% of their body weight, a threshold that begins to approach the range seen after bariatric surgery. In an extension cohort of participants who started with a BMI of 35 or higher and continued to 104 weeks, the 12 mg dose reached 30.3%, or roughly 85 lbs.
Those headline figures reflect an efficacy estimand, the effect if participants stay on treatment. BioPharma Dive noted that under an intent-to-treat analysis, which counts everyone regardless of whether they kept taking the drug, the 12 mg figure lands closer to 25%. All doses met the trial’s primary and key secondary endpoints for weight and cardiometabolic measures.
The response drew a notably strong analyst reaction. RBC Capital Markets’ Trung Huynh called the combination of a clean safety profile and efficacy across all doses “a clean win” for Lilly, while Leerink Partners’ David Risinger said the data were “raising the bar for future novel obesity drug developers.”
Safety followed the familiar incretin pattern: gastrointestinal effects, front-loaded during dose escalation. At 12 mg, 42.4% reported nausea (versus 14.8% on placebo), 32.0% diarrhea, and 26.1% constipation. Discontinuations for adverse events were 11.3% at 12 mg and roughly 4% at the 4 mg dose, below the placebo rate.
A few caveats matter. These are topline figures from a company release, not a peer-reviewed publication; Lilly said full results would be presented at the American Diabetes Association Scientific Sessions the following month. Kenneth Custer of Lilly framed retatrutide as broadening a “patient-centric” menu of obesity options rather than replacing existing ones. Further TRIUMPH trials are due through 2026, including TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease). Those readouts, and eventual regulatory filings for which no date has been disclosed, will determine how the headline numbers hold up across broader populations.